Does hsCRP provide insights into an inflammatory phenotype of knee osteoarthritis?

Abstract excerpt

OBJECTIVE: Posthoc analysis of a canakinumab trial showed a risk reduction of joint replacement in participants with cardiac disease and elevated hsCRP (≥2mg/dL). We determined if hsCRP could serve as a marker to identify an inflammatory OA phenotype characterized by intra-articular synovitis. METHOD: We used data from the NIH-funded MOST Study, where participants had baseline knee MRIs and hsCRP assays....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Aged
• Share to Antibodies, Monoclonal, Humanized